ReviewThyroid : official journal of the American Thyroid Association2016
Management of Invasive Differentiated Thyroid Cancer.
Review in Thyroid : official journal of the American Thyroid Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Guideline for the Surgical Management of Locally Invasive Differentiated Thyroid Cancer From the Korean Society of Head and Neck Surgery.Clinical and experimental otorhinolaryngology · 2023Guideline
- Tracheal and Cricotracheal Resection With End-to-End Anastomosis for Locally Advanced Thyroid Cancer: A Systematic Review of the Literature on 656 Patients.Frontiers in endocrinology · 2021Pooled it
- Surgical Management and Outcomes in Advanced Thyroid Cancer: Insights from a Single-Institution Experience.Journal of clinical medicine · 2026Article
- Article
- Prognostic factors and treatment responses among patients with gross residual disease in differentiated thyroid cancer.Journal of the Chinese Medical Association : JCMA · 2024Article
- AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling.Neoplasia (New York, N.Y.) · 2024Article
- Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2024Article
- Multi-modal ultrasound multistage classification of PTC cervical lymph node metastasis via DualSwinThyroid.Frontiers in oncology · 2024Article
- Using a CT-based scale to evaluate disease extension and the resectability of locally advanced thyroid cancer.European radiology · 2023Article
- Article
- Post-Surgical Indications to Radioiodine Treatment and Potential Risk Factors for Post-Treatment Recurrence in Patients with Intermediate-Risk Differentiated Thyroid Carcinoma.Journal of personalized medicine · 2023Article
- Integrated metabolic and genetic analysis reveals distinct features of primary differentiated thyroid cancer and its metastatic potential in humans.medRxiv : the preprint server for health sciences · 2023Article
- Identification of a Novel Cuproptosis-Related Gene Signature and Integrative Analyses in Thyroid Cancer.Journal of clinical medicine · 2023Article
- Review
- Interaction of MRPL9 and GGCT Promotes Cell Proliferation and Migration by Activating the MAPK/ERK Pathway in Papillary Thyroid Cancer.International journal of molecular sciences · 2022Article
- Well-Differentiated Thyroid Cancer: Who Should Get Postoperative Radiation?Annals of surgical oncology · 2022Article
- FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.Journal of experimental & clinical cancer research : CR · 2022Article
- Development of a Risk Predictive Model for Evaluating Immune Infiltration Status in Invasive Thyroid Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Prognostic factors in patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatmentZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021Article
- Advancements in the treatment of differentiated thyroid cancer.Therapeutic advances in endocrinology and metabolism · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundInvasive disease is a poor prognostic factor for patients with differentiated thyroid cancer (DTC). Uncontrolled central neck disease is a common cause of distressing death for patients presenting in this manner. Advances in assessment and management of such cases have led to significant improvements in outcome for this patient group. This article reviews the patterns of invasion and a contemporary approach to investigation and treatment of patients with invasive DTC. SUMMARY: Aerodigestive tract invasion is reported in around 10% of case series of DTC. Assessment should include not only clinical history and physical examination with endoscopy as indicated, but ultrasound and contrast-enhanced cross-sectional imaging. Further studies including positron emission tomography should be considered, particularly in recurrent cases that are radioactive iodine (RAI) resistant. Both the patient and the extent of disease should be carefully assessed prior to embarking on surgery. The aim of surgery is to resect all gross disease. When minimal visceral invasion is encountered early, "shave" procedures are recommended. In the setting of transmural invasion of the airway or esophagus, however, full thickness excision is required. For intermediate cases in which invasion of the viscera has penetrated the superficial layers but is not evident in the submucosa, opinion is divided. Early reports recommended an aggressive approach. More recently authors have tended to recommend less aggressive resections with postoperative adjuvant therapies. The role of external beam radiotherapy continues to evolve in DTC with support for its use in patients considered to have RAI-resistant tumors.
conclusionsPatients with invasive DTC require a multidisciplinary approach to investigation and treatment. With detailed assessment, appropriate surgery, and adjuvant therapy when indicated, this patient group can expect durable control of central neck disease, despite the aggressive nature of their primary tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.